This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baranzelli, M. C. Articles by Patte, C. Search for Related Content PubMed PubMed Citation Articles by Baranzelli, M. C. Articles by Patte, C. Social Bookmarking                            What's this?

Prognostic Factors in Children With Localized Malignant Nonseminomatous Germ Cell Tumors

From CRLC Oscar Lambret, Lille; CRLC Val d Aurelle Paul Lamarque, Montpellier; Institut Curie, Paris; CHRU Purpan, Toulouse; CHRU Sud, Rennes; Institut Gustave-Roussy, Villejuif, France; and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom.

Address reprint requests to Marie Christine Baranzelli, MD, Pediatric Department, Centre Oscar Lambret, 3 rue F Combemale, BP 307, 59020 Lille Cédex, France; email mc-baranzelli{at}o-lambret.fr

PURPOSE: Prognostic factors were studied in children older than 1 year who were treated with chemotherapy for extracranial localized malignant non seminomatous germ cell tumors.

PATIENTS AND METHODS: Data from two consecutive protocols were pooled. The TGM 85 (1985-1989) protocol consisted of alternating courses of cyclophosphamide, dactinomycin and vinblastine, bleomycin, and cisplatin at a dose of 100 mg/m² per course. The TGM 90 (1990-1994) protocol was initiated with carboplatin 400 mg/m² substituted for cisplatin as the only modification to the previous protocol.

RESULTS: We examined alpha-fetoprotein (AFP) levels, disease stage, and primary site and identified three prognostic groups. Patients with a poor prognosis had either an AFP level 10,000 ng/mL or stage III disease and a sacrococcygeal or mediastinal primary site; such patients represented 46% of the patient population and experienced a 43% 3-year failure-free survival rate and a 77% overall survival rate. Patients with a good prognosis had an AFP level less than 10,000 ng/mL, stage I or II disease, and a testicular, ovarian, perineal, or retroperitoneal primary site; such patients represented 22% of the patient population and experienced no treatment failures. The other patients were classified in the intermediate prognosis group and represented 37% of the patient population, with an 81% 3-year failure-free survival rate and a 92% overall survival rate.

CONCLUSION: Initial AFP level, disease stage, and primary site are the most important prognostic factors in this analysis. Prognostic models for pediatric germ cell tumors should allow the stratification of patients for a risk-adapted approach to treatment.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. M. Green Chemotherapy for the Treatment of Children and Adolescents With Malignant Germ Cell Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3297 - 3298. [Full Text] [PDF]

				N. Marina, W. B. London, A. L. Frazier, S. Lauer, F. Rescorla, B. Cushing, M. H. Malogolowkin, R. P. Castleberry, R. B. Womer, and T. Olson Prognostic Factors in Children With Extragonadal Malignant Germ Cell Tumors: A Pediatric Intergroup Study J. Clin. Oncol., June 1, 2006; 24(16): 2544 - 2548. [Abstract] [Full Text] [PDF]

				B. Cushing, R. Giller, J. W. Cullen, N. M. Marina, S. J. Lauer, T. A. Olson, P. C. Rogers, P. Colombani, F. Rescorla, D. F. Billmire, et al. Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882 J. Clin. Oncol., July 1, 2004; 22(13): 2691 - 2700. [Abstract] [Full Text] [PDF]

				G. Calaminus, D.T. Schneider, J.P.M. Bokkerink, H. Gadner, D. Harms, R. Willers, and U. Gobel Prognostic Value of Tumor Size, Metastases, Extension into Bone, and Increased Tumor Marker in Children With Malignant Sacrococcygeal Germ Cell Tumors: A Prospective Evaluation of 71 Patients Treated in the German Cooperative Protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89 J. Clin. Oncol., March 1, 2003; 21(5): 781 - 786. [Abstract] [Full Text] [PDF]

				U. Gobel, D. T. Schneider, G. Calaminus, H. Jurgens, H. J. Spaar, W. Sternschulte, K. Waag, and D. Harms Multimodal Treatment of Malignant Sacrococcygeal Germ Cell Tumors: A Prospective Analysis of 66 Patients of the German Cooperative Protocols MAKEI 83/86 and 89 J. Clin. Oncol., April 1, 2001; 19(7): 1943 - 1950. [Abstract] [Full Text] [PDF]

				D. T. Schneider, R. Wessalowski, G. Calaminus, H. Pape, M. Bamberg, J. Engert, K. Waag, H. Gadner, and U. Gobel Treatment of Recurrent Malignant Sacrococcygeal Germ Cell Tumors: Analysis of 22 Patients Registered in the German Protocols MAKEI 83/86, 89, and 96 J. Clin. Oncol., April 1, 2001; 19(7): 1951 - 1960. [Abstract] [Full Text] [PDF]

				J. R. Mann, F. Raafat, K. Robinson, J. Imeson, P. Gornall, M. Sokal, E. Gray, P. McKeever, J. Hale, S. Bailey, et al. The United Kingdom Children's Cancer Study Group's Second Germ Cell Tumor Study: Carboplatin, Etoposide, and Bleomycin Are Effective Treatment for Children With Malignant Extracranial Germ Cell Tumors, With Acceptable Toxicity J. Clin. Oncol., November 15, 2000; 18(22): 3809 - 3818. [Abstract] [Full Text] [PDF]

				D. T. Schneider, G. Calaminus, H. Reinhard, P. Gutjahr, B. Kremens, D. Harms, and U. Gobel Primary Mediastinal Germ Cell Tumors in Children and Adolescents: Results of the German Cooperative Protocols MAKEI 83/86, 89, and 96 J. Clin. Oncol., February 14, 2000; 18(4): 832 - 832. [Abstract] [Full Text] [PDF]